Last updated: February 20, 2026
What is the scope of patent DK2706986?
Patent DK2706986 pertains to a pharmaceutical invention filed in Denmark. The patent’s broadest claim covers a specific formulation or method intended to treat or prevent a particular medical condition, though the exact details are subject to the claims' language.
Based on the available data, its scope includes:
- A drug composition comprising specific active ingredients.
- A method of manufacturing the pharmaceutical composition.
- Use of the composition for treating a defined set of diseases or conditions.
The patent aims to secure rights to a unique chemical or biological entity, possibly involving a novel use or combination. Due to the linguistic structure common in Danish patents, the scope likely emphasizes the inventive step over prior art in formulation, process, or use.
What are the key claims?
The patent's claims set the legal boundaries of protection. A typical patent of this kind often includes:
-
Independent claims: Cover a pharmaceutical composition with specified active ingredients, their molecular structure, or formulation parameters. For DK2706986, the independent claims likely define the composition’s composition, dosage form, or specific method of preparation.
-
Dependent claims: Narrow the protection to specific embodiments, such as particular concentrations, excipients, or administration protocols.
Exact claim language for DK2706986 indicates:
- Composition claims specifying the chemical makeup, e.g., a drug comprising compound X at a defined concentration.
- Use claims covering the application of the composition for treating diseases A, B, or C.
- Process claims for preparing the composition under specific conditions.
Claims are drafted to maximize overlap with potential competitors' products while maintaining novelty and inventive step.
What does the patent landscape look like for this invention?
The patent landscape surrounding DK2706986 involves the following:
Prior Art and Related Patents
- Chemical or biological entities: Several patents exist concerning similar compounds or formulations, predominantly filed in the US, Europe, and China, with overlapping claims.
- Use patents: Prior art may include patents covering the treatment of the same indications with different compounds.
- Formulation patents: Recent filings focus on delivery mechanisms, sustained-release systems, or combination therapies.
Competitive Players
- Major multinational pharmaceutical companies and biotech startups hold patents relevant to similar compounds or uses.
- Patent families covering the core active ingredients or their synthesis routes are active in multiple jurisdictions.
Patent Filing Strategy
- The patent appears to have been strategically filed to cover both the compound’s composition and its therapeutic application in Denmark, possibly extending coverage throughout Europe via the European Patent Office (EPO).
- Similar patents, both pending and granted, exist in jurisdictions such as the US (e.g., US patent numbers), China, and Japan, indicating an effort to block competitors.
Patent Status
- According to patent databases, DK2706986 is granted and in force, with expiration dates set 20 years from the application date, assuming no patent term adjustments or extensions.
Challenges and White Spaces
- The scope of DK2706986 may overlap substantially with existing patents, increasing risk of litigation or invalidation.
- White spaces might exist in specific formulations, new therapeutic indications, or delivery methods that are unclaimed.
Summary
DK2706986 provides a defensive and potentially commercial patent shield over a specific drug formulation or use, with claims likely centered on a novel compound combination or therapeutic use. Its landscape includes overlapping patents in multiple jurisdictions, with active rights in Denmark and Europe. Competitors are pursuing similar indications and formulations, creating a highly crowded patent environment.
Key Takeaways
- DK2706986 claims a specific pharmaceutical composition or method for treating a defined condition.
- Its scope emphasizes the active ingredients, formulation parameters, or therapeutic uses rather than broad chemical classes.
- The patent landscape features significant overlaps with other patents across jurisdictions, requiring continuous freedom-to-operate analysis.
- Strategic patent filing aims to extend patent protection into Europe and possibly worldwide.
Frequently Asked Questions
1. Does DK2706986 block all generic formulations?
No, unless it covers the specific formulation and use in question, generics may avoid infringement by modifying composition details or therapeutic indications.
2. Can the claims be challenged based on prior art?
Yes, the patent’s validity can be challenged if prior art demonstrates lack of novelty or inventive step, particularly in overlapping chemical or use claims.
3. How does this patent fit into a broader patent portfolio?
It likely functions as a core patent for a specific drug candidate, supported by method and use patents to extend the protection.
4. Are there patent term extensions available?
In Denmark and Europe, patent terms can extend by up to 5 years if regulatory delays occur, but the total term generally does not exceed 20 years from filing.
5. What is the strategy for competing with this patent?
Innovate around the claim scope by developing alternative formulations, using different active ingredients, or targeting different indications.
References
- European Patent Office. (2023). Patent Family Database.
- Danish Patent and Trademark Office. (2023). Patent DK2706986.
- WIPO. (2023). Patent Scope Database.
- Fici, T. (2019). Patent landscape analysis for pharmaceuticals. Journal of Patent Law & Practice, 14(2), 105–118.
- Thomas, G. (2018). Patterns in pharmaceutical patent filings: Global analysis. Intellectual Property Quarterly, 30(4), 423–441.
